Hoxton Financial’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Hoxton Financial’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$277K	Hold	216	–	–	0.14%	63
2015 Q4	$531K	Hold	216	–	–	0.26%	31
2015 Q3	$239K	Buy	216 +10	+5%	+$11.6K	0.11%	67
2015 Q2	$207K	Hold	206	–	–	0.09%	80
2015 Q1	$209K	Buy	206 +205	+20,500%	+$677K	0.09%	77
2014 Q4	$3K	Sell	1 -11	-92%	-$33.7K	﹤0.01%	294
2014 Q3	$36K	Hold	12	–	–	0.02%	143
2014 Q2	$47K	Buy	12 +4	+50%	+$15.1K	0.02%	136
2014 Q1	$46K	Buy	+8	New	+$42.1K	0.02%	137

Other funds holding NBSE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Bailard Foster City, California $4.91B AUM 31.75% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

GBA

Garrison Bradford & Associates New York $92.2M AUM 19.08% 1-Year Est. Return

Hoxton Financial's NBSE Position: Q1 2016 in Review

Hoxton Financial held its NeuBase Therapeutics, Inc. Common Stock (NBSE) position steady in Q1 2016 at 216 shares worth $277K. The position accounts for 0.14% of the portfolio, ranked #63.

Hoxton Financial first reported a position in NBSE in Q1 2014 and has held it in 9 quarters since. The position peaked at $531K in Q4 2015. 50 funds tracked by Wall St. Rank hold NBSE as of Q1 2016.

Hoxton Financial held 216 shares of NeuBase Therapeutics, Inc. Common Stock worth $277K as of Q1 2016.
Hoxton Financial left its NeuBase Therapeutics, Inc. Common Stock share count unchanged in Q1 2016.
NeuBase Therapeutics, Inc. Common Stock made up 0.14% of Hoxton Financial's portfolio in Q1 2016, its #63 holding.
Hoxton Financial first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q1 2014 and has held it in 9 quarters since.
Hoxton Financial's NeuBase Therapeutics, Inc. Common Stock position peaked at $531K in Q4 2015.
50 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q1 2016.

Based on Hoxton Financial's 13F filing for Q1 2016, filed 29 Apr 2016.